ProShare Advisors LLC - REVANCE THERAPEUTICS INC ownership

REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 152 filers reported holding REVANCE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 2.06 and the average weighting 0.2%.

Quarter-by-quarter ownership
ProShare Advisors LLC ownership history of REVANCE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$190,242
-53.9%
16,586
+1.8%
0.00%0.0%
Q2 2023$412,249
-16.0%
16,288
+6.9%
0.00%
-50.0%
Q1 2023$490,977
+54.7%
15,243
-11.3%
0.00%
+100.0%
Q4 2022$317,383
-16.3%
17,193
+22.3%
0.00%0.0%
Q3 2022$379,000
+102.7%
14,057
+3.8%
0.00%0.0%
Q2 2022$187,000
-53.2%
13,541
-34.1%
0.00%0.0%
Q1 2022$400,000
-3.4%
20,556
-19.2%
0.00%0.0%
Q4 2021$414,000
-38.9%
25,425
+4.5%
0.00%
-50.0%
Q3 2021$678,000
-26.4%
24,340
-21.6%
0.00%
-33.3%
Q2 2021$921,000
+23.5%
31,062
+16.4%
0.00%
+50.0%
Q1 2021$746,000
+8.7%
26,677
+10.2%
0.00%
-33.3%
Q4 2020$686,000
+48.8%
24,210
+32.0%
0.00%
+50.0%
Q3 2020$461,000
+12.2%
18,338
+8.9%
0.00%0.0%
Q2 2020$411,000
+174.0%
16,834
+66.3%
0.00%
+100.0%
Q1 2020$150,000
-41.9%
10,122
-36.2%
0.00%0.0%
Q4 2019$258,000
+17.3%
15,873
-6.4%
0.00%0.0%
Q3 2019$220,000
+0.5%
16,954
+0.3%
0.00%0.0%
Q2 2019$219,000
-27.2%
16,895
-11.6%
0.00%
-50.0%
Q1 2019$301,000
-6.5%
19,114
+19.5%
0.00%0.0%
Q4 2018$322,000
-32.1%
15,994
-16.2%
0.00%
-33.3%
Q3 2018$474,000
-12.7%
19,078
-3.6%
0.00%
-25.0%
Q2 2018$543,000
-13.1%
19,781
-2.6%
0.00%0.0%
Q1 2018$625,000
-12.8%
20,307
+1.2%
0.00%
-20.0%
Q4 2017$717,000
+37.6%
20,069
+6.2%
0.01%0.0%
Q3 2017$521,000
+12.5%
18,898
+7.9%
0.01%0.0%
Q2 2017$463,000
+23.8%
17,521
-2.7%
0.01%
+25.0%
Q1 2017$374,000
-18.3%
18,003
-18.6%
0.00%
-20.0%
Q4 2016$458,000
+41.4%
22,124
+10.7%
0.01%0.0%
Q3 2016$324,000
+0.6%
19,985
-15.6%
0.01%
+25.0%
Q2 2016$322,000
-19.9%
23,688
+2.9%
0.00%
-33.3%
Q1 2016$402,000
-53.4%
23,018
-8.8%
0.01%
-40.0%
Q4 2015$862,000
+46.6%
25,236
+27.7%
0.01%
+25.0%
Q3 2015$588,000
-12.9%
19,762
-6.4%
0.01%
-11.1%
Q2 2015$675,000
+56.6%
21,106
+1.6%
0.01%
+80.0%
Q1 2015$431,000
+45.1%
20,775
+18.4%
0.01%
+66.7%
Q4 2014$297,00017,5440.00%
Other shareholders
REVANCE THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Essex Woodlands Management, Inc. 3,342,047$94,714,00024.58%
Palo Alto Investors LP 2,673,313$75,762,0003.97%
Evolutionary Tree Capital Management, LLC 89,348$2,532,0001.93%
RICE HALL JAMES & ASSOCIATES, LLC 1,121,152$31,773,0001.12%
ArrowMark Colorado Holdings LLC 2,964,135$84,004,0000.65%
Rhenman & Partners Asset Management AB 220,000$6,235,0000.51%
Fosun International Ltd 233,841$6,627,0000.43%
OSTERWEIS CAPITAL MANAGEMENT INC 174,970$4,959,0000.30%
ESSEX INVESTMENT MANAGEMENT CO LLC 76,671$2,173,0000.27%
Tekla Capital Management LLC 213,808$6,059,0000.21%
View complete list of REVANCE THERAPEUTICS INC shareholders